Researchers managed to develop and experiment with a vaccine for a kidney cancer successfully, as the bodies of patients who participated in the study were able to generate a successful anti -cancer immune response after obtaining a specially designed vaccine for each of them. These vaccines are prepared to train the immune system in the body to identify and eliminate any cells and development. The disease is no longer for any of the participants throughout the three years of study.
The study was conducted by researchers from Yale University and the Dana Farper Cancer Center in the United States, and its results were published in the “Nature” magazine (Nature) on February 5th, and the Yurrick Alert website was written about.
Cancer cancer pure renal
Clear Cell Cell Cell Corcinoma is called the name of the tumor under the microscope. Where the cells in the tumor look clear, like bubbles. The net renal cell cancer is the most common type of kidney cancer in adults, and it constitutes about 80% of all cases of renal cell cancer, according to the National Cancer Institute website in the United States.
Patients with nets in the third or fourth stage are treated with a tumor removal surgery. The surgery can follow immunotherapy using the “Pembrolizumab” which stimulates an immune response that reduces the risk of cancer. However, about two -thirds of patients are still vulnerable to the return of the disease and have limited therapeutic options.
A vaccine for each patient
The researchers treated 9 patients with net cancer in the third or fourth stage with the vaccine after surgery. 5 patients also received “iPilimumab” with the vaccine.
A special vaccine was produced for each patient using the tumor tissue that was removed from it during surgery. The team extracted the molecular features from the tumor cells that distinguish it from normal cells. These features, called new antigens, are small fragments of proteins in cancer, but are not present in any other cells in the body.
The team used predictive algorithms to determine which of these new antigens should be included in the vaccine based on the possibility of creating an immune response. Then the vaccine was manufactured and given to the patient in a series of initial doses, followed by two reinforced doses.
Some patients have suffered allergic reactions to the vaccine injection site, and some have suffered from symptoms similar to influenza, but no stronger side effects were reported.
The team found that the vaccine motivated the immune response within 3 weeks, and the number of T -immune cells caused by the vaccine increased by 166 times, and these cells remained in the body at high levels for up to 3 years. Laboratory studies also showed that the T cells caused by the vaccine were active against the patient’s tumor cells.